Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Mar 16;14(2):R38. doi: 10.1186/cc8916

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2010 Pandharipande et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Prevalence of delirium while on study drug. The top panel demonstrates that, among all patients, those sedated with dexmedetomidine (DEX) had a 70% lower likelihood of having delirium on any given day compared with patients sedated with lorazepam (LZ). Sepsis did not modify this relation (adjusted P for interaction = 0.94), meaning that dexmedetomidine reduced the risk of developing delirium whether patients had sepsis (lower panel) or not. * Number of patients assessed denotes the number of patients who were alive, in the ICU, and not comatose (Richmond Agitation-Sedation Scale (RASS)-3 or lighter) and are therefore assessable for delirium. Percentages of patients alive and without coma, but with delirium, are represented with black bars if on lorazepam and gray bars if on dexmedetomidine.